Regeneron Pharmaceuticals Inc. (REGN): Today's Featured Drugs Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Regeneron Pharmaceuticals ( REGN) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 0.6%. By the end of trading, Regeneron Pharmaceuticals rose $5.17 (3%) to $175.28 on average volume. Throughout the day, 783,760 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 811,900 shares. The stock ranged in a price between $171.20-$177.99 after having opened the day at $171.20 as compared to the previous trading day's close of $170.11. Other companies within the Drugs industry that increased today were: Atossa Genetics ( ATOS), up 34.3%, Pacific Biosciences of California ( PACB), up 15.4%, KYTHERA Biopharmaceuticals ( KYTH), up 13.7%, and NPS Pharmaceuticals ( NPSP), up 9.3%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $16.39 billion and is part of the health care sector. The company has a P/E ratio of 25.5, above the S&P 500 P/E ratio of 17.7. Shares are down 0.6% year to date as of the close of trading on Monday. Currently there are seven analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and six rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the negative front, Affymax ( AFFY), down 64%, Star Scientific ( STSI), down 17.2%, Savient Pharmaceuticals ( SVNT), down 14.8%, and Ventrus Biosciences ( VTUS), down 8.4%, were all laggards within the drugs industry with Pharmacyclics Incorporated ( PCYC) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE.
null